Famar key facts
as of Oct 2026- Provider of contract manufacturing services intended for the pharmaceutical and healthcare industry.
- Famar is valued at approximately $553.2M as of Oct 2026 (last reported valuation).
- It has raised $5.2M; the latest was PE Growth/Expansion ($5.2M) in Sep 2025.
- Notable investors include European Bank for Reconstruction and Development, York Capital Management, ECM Partners (Slovenia), Metric Capital Partners, MidEuropa.
- Status: Privately Held (backing).
Famar's last reported valuation, Oct 2024. Nothing priced has surfaced since.
- ·Watch Famar: the Monday email on marks, rounds and moves
Famar funding rounds
No funding rounds for Famar are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
Famar valuation
Famar's last reported valuation was $553 million in Oct 2024. No priced round, secondary trade or fund mark has surfaced since.
Famar investors
5 investors are on record for Famar, including European Bank for Reconstruction and Development, York Capital Management, ECM Partners (Slovenia) and Metric Capital Partners.
About Famar
Provider of contract manufacturing services intended for the pharmaceutical and healthcare industry. The company offers pharmaceutical manufacturing and development services starting from development to production and distribution of a broad range of pharmaceutical and consumer care products.
- Sector
- Business Products and Services (B2B)
- HQ
- Athens, Greece
- Founded
- 1949
- Employees
- 1,758
- Website
- famar-group.com/
- Ownership
- Privately Held (backing)
Is this your company? Sign in with your work email to keep it current, or tell us what's wrong.